drugset / Trial / NCT01541956
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-labeled, randomized, multicenter, prospective, parallel group, interventional study to demonstrate the effectiveness of 24 weeks treatment with Vildagliptin 50mg bid as add on to metformin 500 mg bid compared to metformin up to 1000 mg bid in Chinese patients with type 2 diabetes inadequately controlled on sub maximal dosage metformin monotherapy.
Timeline
- Start
- 2012-02
- Primary completion
- 2013-12
- Completion
- 2013-12
Outcome
Met primary endpoint
paper HbA1c reduction of 0.54% at week 24 in the VLDM group was non-inferior and statistically superior compared with 0.40% in the HDM group PMID 27406394 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 500 mg | — |
| Subject | Metformin | Small molecule | 1000 mg | — |
| Subject | Vildagliptin | Other / unclassified | 50 mg | — |